Spots Global Cancer Trial Database for tocilizumab
Every month we try and update this database with for tocilizumab cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia | NCT04007029 | CD19 Positive CD20 Positive Recurrent Chron... Recurrent Diffu... Recurrent Folli... Recurrent Mantl... Recurrent Prima... Recurrent Small... Refractory Chro... Refractory Diff... Refractory Foll... Refractory Mant... Refractory Prim... Refractory Smal... | Chimeric Antige... Cyclophosphamid... Fludarabine Pho... Tocilizumab | 18 Years - 70 Years | Jonsson Comprehensive Cancer Center | |
| A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma | NCT04408638 | Diffuse Large B... | Obinutuzumab Glofitamab Rituxumab Tocilizumab Gemcitabine Oxaliplatin | 18 Years - | Hoffmann-La Roche | |
| A Phase II Study of the Interleukin-6 Receptor Inhibitor Tocilizumab in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma | NCT03999749 | Melanoma | Ipilimumab Nivolumab Tocilizumab | 18 Years - | NYU Langone Health | |
| Tocilizumab and Atezolizumab in Adults With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Refractory to 1st Line Immune Checkpoint Inhibitor-Based Therapy | NCT04691817 | Lung Cancer, No... | Atezolizumab Tocilizumab | 18 Years - | Abramson Cancer Center at Penn Medicine | |
| Efficacy and Safety of Tocilizumab in the Treatment of Generalized Myasthenia Gravis | NCT05067348 | Myasthenia Grav... | Tocilizumab Inj... | 18 Years - 80 Years | Tang-Du Hospital | |
| Preoperative Immunotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck | NCT03708224 | Cancer Carcinoma Squamous Cell C... Head and Neck C... | Atezolizumab Tocilizumab Tiragolumab | 18 Years - | University of California, San Francisco | |
| Study of RO7515629 in Participants With HLA-G Positive Solid Tumors | NCT05769959 | Renal Cell Carc... Non-small Cell ... Pancreatic Aden... Colorectal Canc... Ovarian Neoplas... | RO7515629 tocilizumab | 18 Years - | Hoffmann-La Roche | |
| Tocilizumab for the Prevention of Graft Failure and GVHD in Haplo-Cord Transplantation | NCT04395222 | Hematologic Mal... Bone Marrow Tra... | Tocilizumab Fludarabine Melphalan Anti-thymocyte ... Total Body Irra... | 18 Years - | Weill Medical College of Cornell University | |
| A Phase Ib Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Cibisatamab in Combination With Atezolizumab After Pretreatment With Obinutuzumab in Participants With Previously Treated Metastatic Colorectal Adenocarcinoma | NCT03866239 | Colorectal Canc... | Obinutuzumab Atezolizumab Cibisatamab Tocilizumab | 18 Years - | Hoffmann-La Roche | |
| Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC) | NCT03869190 | Urothelial Carc... Bladder Cancer | Atezolizumab Enfortumab Vedo... Niraparib Magrolimab (Hu5... Tiragolumab Sacituzumab Gov... Tocilizumab Cisplatin Gemcitabine | 18 Years - | Hoffmann-La Roche | |
| A Study Evaluating the Safety and Efficacy of Glofitamab or Mosunetuzumab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and High-Grade Large B-Cell Lymphoma | NCT04313608 | B-cell Lymphoma | Glofitamab Gemcitabine Oxaliplatin Mosunetuzumab Obinutuzumab Tocilizumab | 18 Years - | Hoffmann-La Roche | |
| Safety and ASCT-related Symptom Burden Optimization of Tocilizumab in ASCT Following HD Melphalan Conditioning for Multiple Myeloma Patients | NCT05855122 | Multiple Myelom... | Tocilizumab | 18 Years - 70 Years | The First Affiliated Hospital of Soochow University | |
| Study of Tocilizumab in Patients With Hepatocellular Carcinoma (HCC) Undergoing Transarterial Chemoembolization (TACE) | NCT02997956 | Hepatocellular ... | Tocilizumab Transcatheter A... | 18 Years - | University of Michigan Rogel Cancer Center | |
| Allogeneic or Haploidentical Stem Cell Transplant Followed By High-Dose Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | NCT02057770 | Leukemia, Myelo... | busulfan fludarabine pho... total-body irra... Stem cell trans... cyclophosphamid... tocilizumab | 18 Years - | Washington University School of Medicine | |
| A Study of Tocilizumab (RoActemra/Actemra) in Monotherapy or in Combination With Methotrexate or Other Non-Biologic DMARDs in Participants With Active Rheumatoid Arthritis and an Inadequate Response to Current Non-Biologic DMARD Therapy or the First Anti-TNF Biologic Agent | NCT02046603 | Rheumatoid Arth... | Tocilizumab DMARDs Oral Corticoste... Methotrexate | 18 Years - | Hoffmann-La Roche | |
| A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-Treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma | NCT03075696 | Non-Hodgkin's L... | Glofitamab Obinutuzumab Tocilizumab | 18 Years - | Hoffmann-La Roche | |
| A Study of RO7293583 in Participants With Unresectable Metastatic Tyrosinase Related Protein 1 (TYRP1)-Positive Melanomas | NCT04551352 | Cutaneous Melan... Uveal Melanoma Mucosal Melanom... | RO7293583 Tocilizumab Obinutuzumab Adalimumab | 18 Years - | Hoffmann-La Roche | |
| A Study of Tocilizumab (RoActemra/Actemra) in Monotherapy or in Combination With Methotrexate or Other Non-Biologic DMARDs in Participants With Active Rheumatoid Arthritis and an Inadequate Response to Current Non-Biologic DMARD Therapy or the First Anti-TNF Biologic Agent | NCT02046603 | Rheumatoid Arth... | Tocilizumab DMARDs Oral Corticoste... Methotrexate | 18 Years - | Hoffmann-La Roche | |
| Comparing the Efficacy of Periarticular Bone Structure in Patients Treated With Either Tocilizumab or Tumor Necrosis Factor Blockers | NCT02778789 | Rheumatoid Arth... | Tocilizumab TNF-alpha Inhib... | 18 Years - | University of Erlangen-Nürnberg Medical School | |
| Dose-Escalation Study of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM) | NCT03275103 | Multiple Myelom... | Cevostamab Tocilizumab | 18 Years - | Genentech, Inc. | |
| A Study of Tocilizumab (RoActemra/Actemra) in Patients With Ankylosing Spondylitis Who Have Had an Inadequate Response to Previous Tumor Necrosis Factor (TNF) Antagonist Therapy | NCT01209689 | Spondylitis, An... | Tocilizumab Placebo | 18 Years - | Hoffmann-La Roche | |
| A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies | NCT05207670 | Non-Hodgkin Lym... | Mosunetuzumab (... Mosunetuzumab (... Tocilizumab | 18 Years - | Genentech, Inc. | |
| A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM) | NCT05927571 | Relapsed or Ref... | Cevostamab Elranatamab Tocilizumab | 18 Years - | Genentech, Inc. | |
| A Phase Ib Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Cibisatamab in Combination With Atezolizumab After Pretreatment With Obinutuzumab in Participants With Previously Treated Metastatic Colorectal Adenocarcinoma | NCT03866239 | Colorectal Canc... | Obinutuzumab Atezolizumab Cibisatamab Tocilizumab | 18 Years - | Hoffmann-La Roche | |
| Trastuzumab and Pertuzumab in Combination With Tocilizumab in Subjects With Metastatic HER2 Positive Breast Cancer Resistant to Trastuzumab | NCT03135171 | Breast Cancer | Trastuzumab Pertuzumab Tocilizumab | 18 Years - | University of Michigan Rogel Cancer Center | |
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7443904 in Combination With Glofitamab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma | NCT05219513 | Lymphoma, Non-H... | RO7443904 Glofitamab Obinutuzumab Tocilizumab | 18 Years - | Hoffmann-La Roche | |
| Efficacy and Safety of Tocilizumab in the Treatment of Generalized Myasthenia Gravis | NCT05067348 | Myasthenia Grav... | Tocilizumab Inj... | 18 Years - 80 Years | Tang-Du Hospital | |
| A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia | NCT05091424 | Chronic Lymphoc... | Mosunetuzumab Tocilizumab Venetoclax | 18 Years - | Hoffmann-La Roche | |
| A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer) | NCT03337698 | Carcinoma, Non-... | Atezolizumab Cobimetinib RO6958688 Docetaxel CPI-444 Pemetrexed Carboplatin Gemcitabine Linagliptin Tocilizumab Ipatasertib Bevacizumab Sacituzumab Gov... Radiation Evolocumab Tiragolumab XL092 Camonsertib | 18 Years - | Hoffmann-La Roche | |
| A Phase 1 Study of SAIL66 in Patients With CLDN6-positive Locally Advanced or Metastatic Solid Tumors | NCT05735366 | Solid Tumor | SAIL66 Tocilizumab | 18 Years - | Chugai Pharmaceutical | |
| Study to Evaluate the Safety, Tolerability and Efficacy of Tocilizumab in Participants With Rheumatoid Arthritis (RA) Who Have an Inadequate Response to Non-Biologic Disease Modifying Anti-rheumatic Drugs (DMARDs) and/or Anti-tumor Necrosis Factor (Anti-TNF) Therapy | NCT01362062 | Rheumatoid Arth... | Tocilizumab | 18 Years - | Hoffmann-La Roche | |
| A Study of Tocilizumab (RoActemra/Actemra) in Patients With Ankylosing Spondylitis Who Have Had an Inadequate Response to Previous Tumor Necrosis Factor (TNF) Antagonist Therapy | NCT01209689 | Spondylitis, An... | Tocilizumab Placebo | 18 Years - | Hoffmann-La Roche | |
| A Study Evaluating the Efficacy and Safety of Cevostamab in Prior B Cell Maturation Antigen (BCMA)-Exposed Participants With Relapsed/Refractory Multiple Myeloma | NCT05535244 | Multiple Myelom... | Cevostamab Tocilizumab | 18 Years - | Hoffmann-La Roche | |
| ACTEMRA® for the Treatment of Pediatric Adamantinomatous Craniopharyngioma | NCT05233397 | Adamantinomatou... Recurrent Adama... | Tocilizumab | 1 Year - 25 Years | Nationwide Children's Hospital | |
| Study of Rituximab or Tocilizumab for Patients With Steroid-Dependent Immune-Related Adverse Events (irAEs) | NCT04375228 | Immune-related ... Advanced Solid ... | Rituximab Tocilizumab | 18 Years - | Columbia University | |
| PRONTO Trial (PRophylactic Versus ON-demand Use of TOcilizumab) | NCT06430736 | Myeloma Lymphoma Leukemia | Tocilizumab bef... Tocilizumab at ... | 18 Years - | Insel Gruppe AG, University Hospital Bern | |
| An Open-Label, Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab in Combination With Tiragolumab With or Without Atezolizumab in Participants With B-Cell Non-Hodgkin Lymphoma | NCT05315713 | Non-Hodgkin Lym... | Mosunetuzumab S... Tiragolumab Atezolizumab Tocilizumab | 18 Years - | Hoffmann-La Roche | |
| A Study Evaluating Safety, Pharmacokinetics, Pharmacodynamics, And Clinical Activity Of RO7119929 (TLR7 Agonist) In Participants With Unresectable Advanced Or Metastatic Hepatocellular Carcinoma, Biliary Tract Cancer, Or Solid Tumors With Hepatic Metastases | NCT04338685 | Carcinoma, Hepa... Biliary Tract C... Secondary Liver... Liver Metastase... | RO7119929 Tocilizumab | 18 Years - | Hoffmann-La Roche | |
| Testing the Addition of the Immune Therapy Drugs, Tocilizumab and Atezolizumab, to Radiation Therapy for Recurrent Glioblastoma | NCT04729959 | Diffuse Astrocy... Recurrent Gliob... | Atezolizumab Biospecimen Col... Conventional Su... Fractionated St... Magnetic Resona... Tocilizumab | 18 Years - | National Cancer Institute (NCI) | |
| Neoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior to Radical Prostatectomy | NCT03821246 | Prostate Adenoc... Prostate Cancer Localized Prost... | Atezolizumab Tocilizumab Etrumadenant | 18 Years - | University of California, San Francisco | |
| A Ph 2 Study of Glofitamab Alone or in Combination With Polatuzumab Vedotin or Atezolizumab in Richter's Transformation | NCT06043674 | Chronic Lymphoc... Richter's Trans... | Glofitamab Obinutuzumab Polatuzumab Ved... Atezolizumab Tocilizumab | 18 Years - | Dana-Farber Cancer Institute | |
| A Phase Ib/II Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Participants With B-Cell Non-Hodgkin Lymphoma | NCT03677141 | B-cell Non-Hodg... | Mosunetuzumab Polatuzumab Ved... Rituxumab Cyclophosphamid... Doxorubicin Vincristine Prednisone Tocilizumab | 18 Years - | Hoffmann-La Roche | |
| A Study to Evaluate the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Circulating Tumor (ct)DNA High-Risk Patients With Untreated Diffuse Large B-Cell Lymphoma | NCT04980222 | Lymphoma | Glofitamab Tocilizumab Doxorubicin Vincristine Prednisone Rituximab Cyclophosphamid... | 18 Years - | Hoffmann-La Roche | |
| A Study of Glofitamab in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP), or Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (CHP) in Participants With Non-Hodgkin Lymphomas or With DLBCL | NCT03467373 | B-Cell Lymphoma Non-Hodgkin Lym... | Glofitamab Obinutuzumab (G... Rituximab (R) Tocilizumab Cyclophosphamid... Doxorubicin Vincristine Prednisone Polatuzumab ved... | 18 Years - | Hoffmann-La Roche | |
| A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma | NCT04910568 | Multiple Myelom... | Cevostamab Tocilizumab Pomalidomide Daratumumab Dexamethasone | 18 Years - | Genentech, Inc. | |
| Phase II Trial of Carboplatin +/- Tocilizumab for Metastatic Triple Negative and ER-low Breast Cancers | NCT05846789 | Metastatic Brea... Triple Negative... Estrogen-recept... | Carboplatin Tocilizumab | 18 Years - | Indiana University | |
| A Study of Runimotamab in Participants With Locally Advanced or Metastatic HER2-Expressing Cancers | NCT03448042 | Solid Tumors | Runimotamab Trastuzumab Tocilizumab | 18 Years - | Genentech, Inc. | |
| A Study to Evaluate the Safety, Pharmacokinetics, and Activity of XmAb24306 in Combination With Cevostamab in Participants With Relapsed/Refractory Multiple Myeloma | NCT05646836 | Multiple Myelom... | Cevostamab XmAb24306 Tocilizumab | 18 Years - | Genentech, Inc. | |
| A Phase II Study of the Interleukin-6 Receptor Inhibitor Tocilizumab in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma | NCT03999749 | Melanoma | Ipilimumab Nivolumab Tocilizumab | 18 Years - | NYU Langone Health | |
| Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma | NCT04940299 | Clinical Stage ... Clinical Stage ... Locally Advance... Locally Advance... Locally Advance... Locally Advance... Locally Advance... Locally Advance... Locally Advance... Malignant Solid... Metastatic Blad... Metastatic Blad... Metastatic Lung... Metastatic Mela... Metastatic Rena... Metastatic Uret... Metastatic Uret... Metastatic Uret... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Stage III Bladd... Stage III Lung ... Stage III Renal... Stage III Urete... Stage III Ureth... Stage IIIA Blad... Stage IIIA Lung... Stage IIIB Blad... Stage IIIB Lung... Stage IIIC Lung... Stage IV Bladde... Stage IV Lung C... Stage IV Renal ... Stage IV Ureter... Stage IV Urethr... Stage IVA Lung ... Stage IVB Lung ... Unresectable Me... | Ipilimumab Nivolumab Tocilizumab | 18 Years - | M.D. Anderson Cancer Center | |
| Phase II Trial of Carboplatin +/- Tocilizumab for Metastatic Triple Negative and ER-low Breast Cancers | NCT05846789 | Metastatic Brea... Triple Negative... Estrogen-recept... | Carboplatin Tocilizumab | 18 Years - | Indiana University | |
| A Study Evaluating the Efficacy and Safety of Cevostamab in Prior B Cell Maturation Antigen (BCMA)-Exposed Participants With Relapsed/Refractory Multiple Myeloma | NCT05535244 | Multiple Myelom... | Cevostamab Tocilizumab | 18 Years - | Hoffmann-La Roche | |
| A Study to Evaluate Safety, Pharmacokinetics, and Preliminary Anti-tumor Activity of RO7444973 in Participants With Unresectable and/or Metastatic MAGE-A4-positive Solid Tumors | NCT05129280 | Solid Tumors | RO7444973 Tocilizumab | 18 Years - | Hoffmann-La Roche | |
| A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma | NCT05533775 | Mature B-Cell N... | Obinutuzumab Glofitamab Rituximab Ifosfamide Carboplatin Etoposide Tocilizumab | 6 Months - 30 Years | Hoffmann-La Roche | |
| Evaluating Tocilizumab for Sever COVID-19 Infection in Breast Cancer vs. Non Cancer Pateints | NCT04871854 | Breast Cancer | Tocilizumab traditional Cov... | 18 Years - 85 Years | Beni-Suef University | |
| Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC) | NCT03869190 | Urothelial Carc... Bladder Cancer | Atezolizumab Enfortumab Vedo... Niraparib Magrolimab (Hu5... Tiragolumab Sacituzumab Gov... Tocilizumab Cisplatin Gemcitabine | 18 Years - | Hoffmann-La Roche | |
| A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma | NCT04408638 | Diffuse Large B... | Obinutuzumab Glofitamab Rituxumab Tocilizumab Gemcitabine Oxaliplatin | 18 Years - | Hoffmann-La Roche | |
| An Open-Label, Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab in Combination With Tiragolumab With or Without Atezolizumab in Participants With B-Cell Non-Hodgkin Lymphoma | NCT05315713 | Non-Hodgkin Lym... | Mosunetuzumab S... Tiragolumab Atezolizumab Tocilizumab | 18 Years - | Hoffmann-La Roche | |
| Tocilizumab for Prevention of Respiratory Failure in Patients With Severe COVID-19 Infection | NCT04377659 | COVID-19 | Tocilizumab | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| A Study to Evaluate the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Circulating Tumor (ct)DNA High-Risk Patients With Untreated Diffuse Large B-Cell Lymphoma | NCT04980222 | Lymphoma | Glofitamab Tocilizumab Doxorubicin Vincristine Prednisone Rituximab Cyclophosphamid... | 18 Years - | Hoffmann-La Roche | |
| Tocilizumab for the Prevention of Graft Failure and GVHD in Haplo-Cord Transplantation | NCT04395222 | Hematologic Mal... Bone Marrow Tra... | Tocilizumab Fludarabine Melphalan Anti-thymocyte ... Total Body Irra... | 18 Years - | Weill Medical College of Cornell University | |
| A Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-tumor Activity of RO7616789 in Advanced Small Cell Lung Cancer and Other Neuroendocrine Carcinomas | NCT05619744 | Small Cell Lung... Neuroendocrine ... | RO7616789 Tocilizumab | 18 Years - | Hoffmann-La Roche | |
| Study of Nab-Paclitaxel and Gemcitabine With or Without Tocilizumab in Pancreatic Cancer Patients | NCT02767557 | Unresectable Pa... | Tocilizumab Gemcitabine nab-Paclitaxel | 18 Years - | Herlev Hospital | |
| Safety and ASCT-related Symptom Burden Optimization of Tocilizumab in ASCT Following HD Melphalan Conditioning for Multiple Myeloma Patients | NCT05855122 | Multiple Myelom... | Tocilizumab | 18 Years - 70 Years | The First Affiliated Hospital of Soochow University | |
| Neoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior to Radical Prostatectomy | NCT03821246 | Prostate Adenoc... Prostate Cancer Localized Prost... | Atezolizumab Tocilizumab Etrumadenant | 18 Years - | University of California, San Francisco | |
| A Study to Evaluate Safety, Pharmacokinetics, and Preliminary Anti-tumor Activity of RO7444973 in Participants With Unresectable and/or Metastatic MAGE-A4-positive Solid Tumors | NCT05129280 | Solid Tumors | RO7444973 Tocilizumab | 18 Years - | Hoffmann-La Roche | |
| Study of the Tocilizumab Optimization Timing for CART19 Associated Cytokine Release Syndrome | NCT02906371 | Lymphoblastic L... | Tocilizumab Tocilizumab CART 19 | 1 Year - 24 Years | University of Pennsylvania | |
| A Study of RO7172508 in Patients With Locally Advanced and/or Metastatic CEA-Positive Solid Tumors | NCT03539484 | Solid Tumors | RO7172508 Obinutuzumab Tocilizumab | 18 Years - | Hoffmann-La Roche | |
| A Study Evaluating the Safety of Tocilizumab in Addition to Standard of Care Premedication Given Before Obinutuzumab + Chlorambucil in Participants With Untreated B-Cell Chronic Lymphocytic Leukemia (B-CLL) and Comorbidities | NCT02336048 | B-Cell Chronic ... | Chlorambucil Obinutuzumab Placebo Standard Premed... Tocilizumab | 18 Years - | Hoffmann-La Roche | |
| A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies | NCT05207670 | Non-Hodgkin Lym... | Mosunetuzumab (... Mosunetuzumab (... Tocilizumab | 18 Years - | Genentech, Inc. | |
| A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer | NCT03424005 | Breast Cancer | Capecitabine Atezolizumab Ipatasertib SGN-LIV1A Bevacizumab Chemotherapy (G... Selicrelumab Tocilizumab Nab-Paclitaxel Sacituzumab Gov... Abemaciclib Fulvestrant Ribociclib Inavolisib Inavolisib (9 m... Inavolisib (6 m... Trastuzumab Der... | 18 Years - | Hoffmann-La Roche | |
| A Study to Evaluate the Safety, Pharmacokinetics, and Activity of XmAb24306 in Combination With Cevostamab in Participants With Relapsed/Refractory Multiple Myeloma | NCT05646836 | Multiple Myelom... | Cevostamab XmAb24306 Tocilizumab | 18 Years - | Genentech, Inc. | |
| An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma | NCT03533283 | Non-Hodgkins Ly... | Glofitamab Atezolizumab Obinutuzumab Tocilizumab Polatuzumab Ved... 89Zr-Df-IAB22M2... | 18 Years - | Hoffmann-La Roche | |
| A Study of RO7617991 in Patients With Locally Advanced or Metastatic MAGE-A4-Positive Solid Tumors | NCT06372574 | Refractory Canc... Recurrent Cance... Solid Tumor, Ad... | RO7617991 Tocilizumab | 18 Years - | Genentech, Inc. | |
| A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-Treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma | NCT03075696 | Non-Hodgkin's L... | Glofitamab Obinutuzumab Tocilizumab | 18 Years - | Hoffmann-La Roche | |
| A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of RO7227166 in Combination With Obinutuzumab and in Combination With Glofitamab Following a Pre-Treatment Dose of Obinutuzumab Administered in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma | NCT04077723 | Lymphoma, Non-H... | RO7227166 Obinutuzumab Glofitamab Tocilizumab | 18 Years - | Hoffmann-La Roche | |
| Comparing the Efficacy of Periarticular Bone Structure in Patients Treated With Either Tocilizumab or Tumor Necrosis Factor Blockers | NCT02778789 | Rheumatoid Arth... | Tocilizumab TNF-alpha Inhib... | 18 Years - | University of Erlangen-Nürnberg Medical School | |
| Efficacy and Safety of CDP6038 in Patients With Rheumatoid Arthritis With an Unsuccessful Response to Anti-Tumor Necrosis Factor (Anti-TNF) Therapy | NCT01242488 | Rheumatoid Arth... | CDP6038 CDP6038 CDP6038 Tocilizumab (Ac... CDP6038 CDP6038 CDP6038 Placebo sc Placebo sc Placebo iv | 18 Years - | UCB Pharma | |
| A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer | NCT03424005 | Breast Cancer | Capecitabine Atezolizumab Ipatasertib SGN-LIV1A Bevacizumab Chemotherapy (G... Selicrelumab Tocilizumab Nab-Paclitaxel Sacituzumab Gov... Abemaciclib Fulvestrant Ribociclib Inavolisib Inavolisib (9 m... Inavolisib (6 m... Trastuzumab Der... | 18 Years - | Hoffmann-La Roche | |
| Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia | NCT04007029 | CD19 Positive CD20 Positive Recurrent Chron... Recurrent Diffu... Recurrent Folli... Recurrent Mantl... Recurrent Prima... Recurrent Small... Refractory Chro... Refractory Diff... Refractory Foll... Refractory Mant... Refractory Prim... Refractory Smal... | Chimeric Antige... Cyclophosphamid... Fludarabine Pho... Tocilizumab | 18 Years - 70 Years | Jonsson Comprehensive Cancer Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
